Citizens Capital Markets & Advisory announced the additions of Daniel Berenson and Frankie Beardslee to its life sciences investment banking team. Berenson joins the bank as a Managing Director while Beardslee joins as a Director. 

Berenson and Beardslee bring more than 30 years of combined investment banking experience to their new roles. They will be responsible for continuing to deepen the bank’s relationships with companies and investors in the biotechnology and pharmaceuticals segments. They will both report to David Kellman, Head of Life Sciences and Biopharma Investment Banking at Citizens.

“Dan and Frankie bring a wealth of expertise to their new roles, and they share our commitment to delivering outstanding outcomes for our clients,” Kellman said. “I am excited to welcome bankers of their caliber to Citizens and look forward to all they will achieve as part of our growing healthcare practice.” 

These new additions expand the capabilities of a Citizens life sciences franchise that is growing and experiencing significant momentum across equity capital markets, debt capital markets, and M&A.  

Prior to joining Citizens, Berenson served as a senior managing director at Leerink Partners, helping lead the biopharma strategic advisory practice. Previously, he honed his expertise in the pharmaceutical, biotechnology and specialty pharmaceutical sectors as a senior member of the healthcare groups at Centerview Partners and Guggenheim Partners. Berenson is based in New York. 

Beardslee joins Citizens with a strong track record as a trusted advisor to public and private life sciences companies. He previously served as a senior member of the biotechnology investment banking teams at William Blair and BMO Capital Markets. Most recently, he served as a Director in the financial transactions practice at FGS Global. Beardslee is based in Chicago.